Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057743 · ClinicalTrials.gov registry record
Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03057743 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 4 participants.
The verdict
NCT03057743 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 adult patients at least 18 years, with at least one site of disease outside the liver by at least one type of standard imaging.
Interventions
- DEVICE Positron emission tomography (PET/CT) imaging
- DEVICE radiotracer [18F]ISO-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-04-05 |
| Est. Completion | 2021-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03057743
The ClinicalTrials.gov registry entry for NCT03057743 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Positron emission tomography (PET/CT) imaging is the first listed.
NCT03057743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03057743 about?
NCT03057743 is a clinical study titled "Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer". Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 ad...
What is the current status of trial NCT03057743?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2016-04-05. Estimated completion is 2021-11-01.
What interventions are being tested in trial NCT03057743?
The interventions under investigation include: Positron emission tomography (PET/CT) imaging (DEVICE), radiotracer [18F]ISO-1 (DEVICE).
Who is sponsoring clinical trial NCT03057743?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.